This brand name is authorized in Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Ireland, Israel, Japan, Lithuania, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, United States, South Africa
The drug VELCADE contains one active pharmaceutical ingredient (API):
1
Bortezomib
UNII 69G8BD63PP - BORTEZOMIB
|
Bortezomib is a proteasome inhibitor. It is specifically designed to inhibit the chymotrypsin-like activity of the 26S proteasome in mammalian cells. Inhibition of the 26S proteasome prevents this targeted proteolysis and affects multiple signalling cascades within the cell, ultimately resulting in cancer cell death. |
Below package inserts are available for further reading:
Title | Information Source | Document Type | |
---|---|---|---|
VELCADE Powder for solution | European Medicines Agency (EU) | MPI, EU: SmPC | |
Velcade 3.5 mg powder for solution for injection | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
ATC code | Group title | Classification |
---|---|---|
L01XG01 | Bortezomib | L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XG Proteasome inhibitors |
This drug has been assigned below unique identifiers within the countries it is being marketed:
Country | Identification scheme | Identifier(s) |
---|---|---|
Country: AU | Pharmaceutical Benefits Scheme | Identifier(s): 12219D, 12227M |
Country: BR | Câmara de Regulação do Mercado de Medicamentos | Identifier(s): 514506401156317 |
Country: CA | Health Products and Food Branch | Identifier(s): 02262452 |
Country: EC | Agencia Nacional de Regulación, Control y Vigilancia Sanitaria | Identifier(s): 27.605-1-03-12 |
Country: EE | Ravimiamet | Identifier(s): 1148004, 1364868 |
Country: ES | Centro de información online de medicamentos de la AEMPS | Identifier(s): 04274001 |
Country: FI | Lääkealan turvallisuus- ja kehittämiskeskus | Identifier(s): 017195 |
Country: FR | Base de données publique des médicaments | Identifier(s): 62438913, 69756861 |
Country: GB | Medicines & Healthcare Products Regulatory Agency | Identifier(s): 75131 |
Country: HK | Department of Health Drug Office | Identifier(s): 60429, 63741 |
Country: IL | מִשְׂרַד הַבְּרִיאוּת | Identifier(s): 4829 |
Country: JP | 医薬品医療機器総合機構 | Identifier(s): 4291412D1024 |
Country: LT | Valstybinė vaistų kontrolės tarnyba | Identifier(s): 1031151, 1032114 |
Country: MX | Comisión Federal para la Protección contra Riesgos Sanitarios | Identifier(s): 654M2004 |
Country: NL | Z-Index G-Standaard, PRK | Identifier(s): 75299, 93610 |
Country: NZ | Medicines and Medical Devices Safety Authority | Identifier(s): 11690, 13403 |
Country: PL | Rejestru Produktów Leczniczych | Identifier(s): 100085192, 100194113 |
Country: RO | Agenția Națională a Medicamentului și a Dispozitivelor Medicale | Identifier(s): W42249001, W53033001 |
Country: SG | Health Sciences Authority | Identifier(s): 13064P |
Country: TN | Direction de la Pharmacie et du Médicament | Identifier(s): 15273011H |
Country: TR | İlaç ve Tıbbi Cihaz Kurumu | Identifier(s): 8699593775017 |
Country: US | FDA, National Drug Code | Identifier(s): 63020-049 |
Country: ZA | Health Products Regulatory Authority | Identifier(s): 43/26/0427, A40/26/0005 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.